TQ05310 is an orally active mutant IDH2 inhibitor that targets both IDH2-R140Q (IC50 = 136.9 nM) and IDH2-R172K (IC50 = 37.9 nM) mutants; it suppresses the production of 2-hydroxyglutarate (2-HG) by inhibiting the enzymatic activity of mutant IDH2 and induces differentiation in cells expressing IDH2-R140Q or IDH2-R172K; it can be used in the research of acute myeloid leukemia.